Aerovate Therapeutics FY 2022: net loss $51.5M; diluted EPS −$2.10

Key figures from this report

These are the numbers Aerovate Therapeutics reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Net income−$51.5MAgainst −$23.0M in FY 202110-K income statement, on EDGAR
2. Diluted EPS−$2.10Against −$1.87 in FY 202110-K income statement, on EDGAR
3. Cash and cash equivalents$22.4M−59% from $54.2M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
4. Cash from operations−$39.1MAgainst −$27.4M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables